Bristol-Myers Squibb and AstraZeneca Collaboration

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to research, develop and commercialise select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca diabetes collaboration is dedicated to global patient care and improving patient outcomes in the treatment of type 2 diabetes. The portfolio of type 2 diabetes products developed as a part of the Bristol-Myers Squibb and AstraZeneca collaboration includes the first-in-class SGLT2 inhibitor Forxiga (dapagliflozin), the DPP4 inhibitor Onglyza ® (saxagliptin), Komboglyze (saxagliptin and metformin HCl immediate-release fixed dose combination) and Kombiglyze XR (saxagliptin and metformin HCl extended-release fixed dose combination), which is only available outside the European Union.

In August 2012, Bristol-Myers Squibb completed the acquisition of Amylin Pharmaceuticals. Bristol-Myers Squibb and AstraZeneca then expanded their existing alliance in diabetes to incorporate Amylin’s portfolio of diabetes products, which includes GLP1s Byetta ® (exenatide injection) and Bydureon (exenatide extended-release for injectable suspension), both the first to be approved in their class and now available in the U.S. and Europe, as well as the first-in-class Amylin mimetic Symlin ® (pramlintide acetate injection), which is only available in the U.S. Eli Lilly and Amylin amicably terminated their joint collaboration in November 2011 for exenatide and began to transition global responsibility for the exenatide franchise to Amylin, starting in the U.S. and targeting the transition for all markets by the end of 2013. Bristol-Myers Squibb and AstraZeneca are now working to transition markets outside the U.S. in which Lilly markets and sells exenatide into the expanded Bristol-Myers Squibb and AstraZeneca alliance.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

If you liked this article you might like

CEOs Are Dropping Like Flies

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting